Alyeska Investment Group
CSTL icon

Alyeska Investment Group’s Castle Biosciences CSTL Stock Holding History

Alyeska Investment Group’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-149,792
Closed -$5.65M – 489
2020
Q2 		$5.65M Buy
+149,792
New +$5.12M 0.09% 254
2020
Q1 		– Sell
-16,018
Closed -$551K – 388
2019
Q4 		$551K Sell
16,018
-166,254
-91% -$4.07M 0.01% 351
2019
Q3 		$3.3M Buy
+182,272
New +$4.04M 0.05% 258

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Alyeska Investment Group's CSTL Position: Q3 2020 in Review

Alyeska Investment Group sold out of Castle Biosciences (CSTL) in Q3 2020, closing a stake of 149,792 shares — an estimated $5.65M sold.

Alyeska Investment Group first reported a position in CSTL in Q3 2019 and held it in 3 quarters. The position peaked at $5.65M in Q2 2020. 144 funds tracked by Wall St. Rank hold CSTL as of Q3 2020.

  • Alyeska Investment Group reported no remaining Castle Biosciences position as of Q3 2020 after selling out during the quarter.
  • Alyeska Investment Group sold 149,792 Castle Biosciences shares in Q3 2020, an estimated $5.65M.
  • Alyeska Investment Group first reported a position in Castle Biosciences in Q3 2019 and held it in 3 quarters.
  • Alyeska Investment Group's Castle Biosciences position peaked at $5.65M in Q2 2020.
  • 144 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2020.

Based on Alyeska Investment Group's 13F filing for Q3 2020, filed 16 Nov 2020.